Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00000392 · ClinicalTrials.gov registry record · Phase 2
Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.
A Phase 2 study, sponsored by National Institute of Mental Health (NIMH).
- Completed
- Registry status
- Phase 2
- Development phase
- 215
- Enrollment target
NCT00000392 is a Phase 2 study that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 215 participants.
The verdict
NCT00000392, a Phase 2 study, has completed, sponsored by National Institute of Mental Health (NIMH).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 215 participants
- Enrollment target
Study Summary
To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals. Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients. Patients are randomized to receive either peptide T or placebo for the first 6 months. All patients then receive open-label peptide T for approximately 6 additional months. Neuropsychologic tests are used to determine drug effects.
Interventions
- DRUG Placebo
- DRUG Peptide T
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 215 participants |
| Start Date | 1990-01 |
| Est. Completion | 1996-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000392
The ClinicalTrials.gov registry entry for NCT00000392 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 215 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00000392 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00000392 about?
NCT00000392 is a clinical study titled "Phase II Study of the Efficacy of Peptide T in HIV-Positive Individuals With Cognitive Impairment.". To evaluate the chemical efficacy and safety of intranasally administered peptide T on neurocognitive function in HIV seropositive individuals. Previous studies have shown that treatment with peptide T can result in cognitive improvement in HIV-infected patients. Patients are randomized to receive...
What is the current status of trial NCT00000392?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 215 participants. The study started on 1990-01. Estimated completion is 1996-08.
What interventions are being tested in trial NCT00000392?
The interventions under investigation include: Placebo (DRUG), Peptide T (DRUG).
Who is sponsoring clinical trial NCT00000392?
This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.